3 diabetes drugs beat rivals in preventing heart disease

04/7/2011 | U.S. News & World Report

Diabetes drugs metformin, gliclazide and repaglinide proved more effective than other treatments in lowering the risks of cardiovascular disease and death, according to a study of more than 100,000 Danish people older than 20. Glimepiride, glibenclamide, glipizide and tolbutamide were linked to a higher risk of all-cause mortality as well as to a higher risk of heart attack, stroke and cardiovascular death, the study found.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA